NCT00314262View on ClinicalTrials.gov

Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Precancerous Conditions
Interventions
DRUG

Erlotinib & Celecoxib

"Erlotinib given orally, once daily (dose escalation from 50 mg, 75 mg, or 100 mg) continuously for 6 months in the phase I portion.~Celecoxib given 400 mg orally BID continuously for 6 months."

Trial Locations (1)

30322

Emory University Winship Cancer Institute, Atlanta

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Emory University

OTHER

NCT00314262 - Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor | Biotech Hunter | Biotech Hunter